Dendritic Cells in Shaping Anti-Tumor T Cell Response
Cancers · 13.06.2024 · 16 (12) · 2211
DOI: 10.3390/cancers16122211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.06.2024. Verfasst von Luciano Mazzoccoli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH/NCI, Ohio State University Comprehensive Cancer Center.
Abstract (Originalsprache)
Among professional antigen-presenting cells, dendritic cells (DCs) orchestrate innate and adaptive immunity and play a pivotal role in anti-tumor immunity. DCs are a heterogeneous population with varying functions in the tumor microenvironment (TME). Tumor-associated DCs differentiate developmentally and functionally into three main subsets: conventional DCs (cDCs), plasmacytoid DCs (pDCs), and monocyte-derived DCs (MoDCs). There are two major subsets of cDCs in TME, cDC1 and cDC2. cDC1 is critical for cross-presenting tumor antigens to activate cytotoxic CD8+ T cells and is also required for priming earlier CD4+ T cells in certain solid tumors. cDC2 is vital for priming anti-tumor CD4+ T cells in multiple tumor models. pDC is a unique subset of DCs and produces type I IFN through TLR7 and TLR9. Studies have shown that pDCs are related to immunosuppression in the TME through the secretion of immunosuppressive cytokines and by promoting regulatory T cells. MoDCs differentiate separately from monocytes in response to inflammatory cues and infection. Also, MoDCs can cross-prime CD8+ T cells. In this review, we summarize the subsets and functions of DCs. We also discuss the role of different DC subsets in shaping T cell immunity in TME and targeting DCs for potential immunotherapeutic benefits against cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
- The Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Förderung
- NIH/NCI
- Ohio State University Comprehensive Cancer Center
Zitieren
APA
Mazzoccoli, L., & Liu, B. (2024). Dendritic Cells in Shaping Anti-Tumor T Cell Response. Cancers, 16(12), 2211. https://doi.org/10.3390/cancers16122211
Vancouver
Mazzoccoli L, Liu B. Dendritic Cells in Shaping Anti-Tumor T Cell Response. Cancers. 2024;16(12):2211. doi:10.3390/cancers16122211
BibTeX
@article{Mazzoccoli2024,
author = {Mazzoccoli, Luciano and Liu, Bei},
title = {Dendritic Cells in Shaping Anti-Tumor T Cell Response},
journal = {Cancers},
year = {2024},
volume = {16},
number = {12},
pages = {2211},
doi = {10.3390/cancers16122211}
}
EUVIMED